- Home
- WLDN vs GHRS Comparison
WLDN vs GHRS Comparison
Compare WLDN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WLDN | GHRS |
|---|---|---|
| Founded | 1964 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WLDN | GHRS |
|---|---|---|
| Price | $80.19 | $14.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $123.25 | $41.38 |
| AVG Volume (30 Days) | ★ 335.2K | 203.0K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $273,352,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.05 | N/A |
| P/E Ratio | $23.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.43 | $7.98 |
| 52 Week High | $137.00 | $19.51 |
Technical Indicators
Market Signals| Indicator | WLDN | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 44.44 |
| Support Level | $74.75 | $13.75 |
| Resistance Level | $119.59 | $14.80 |
| Average True Range (ATR) | 3.67 | 0.85 |
| MACD | 1.37 | -0.17 |
| Stochastic Oscillator | 60.42 | 38.14 |
Price Performance
Historical ComparisonAbout WLDN Willdan Group Inc.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.